Список литературы

1. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood. 2009; 113(11): 2386 - 93. doi: 10.1182/blood-2008-07-162503.

2. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. PresseMed. 2014; 43(4 Pt2): e49 - 59. doi: 10.1016/j.lpm.2014.01.010.

3. Меликян А.Л., Пустовая Е.И., Калинина М.В., Володичева Е.М., Капорская Т.С., Ильясов Р.К., Бабаева Т.Н., Беккер О.М., Богова В.С., Зотина Е.Н., Зотова И.И., Контиевский И.Н., Пяткова О.А., Соколова И.С., Федорова Н.А., Шестопалова И.А., Колошейнова Т.И., Егорова Е.К., Куликов С.М. Эпидемиологические характеристики первичной иммунной тромбоцитопении у взрослого населения в Российской Федерации. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2017; N 4(10): 558 - 559.

4. Provan D., Stasi R., Newland A.S., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168 - 86. doi: 10.1182/blood-2009-06-225565.

5. Neunert C., Lim W., Crowther M., Cohen A., Solberg L.Jr., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16): 4190 - 207. doi: 10.1182/blood-2010-08-302984.

6. Масчан А.А., Румянцев А.Г., Ковалева Л.Г., Афанасьев Б.В., Поспелова Т.И., Зарицкий А.Ю. и др. Рекомендации Российского совета экспертов по диагностике и лечению пациентов первичной иммунной тробоцитопенией. Онкогематология. 2010; 3: 36 - 45.

7. Ковалева Л.Г., Пустовая Е.И., Сафонова Т.И. Идиопатическая тромбоцитопеническая пурпура (ИТП) взрослых. Первичная иммунная тромбоцитопения (ИТП) взрослых. Болезнь Верльгофа. М.: Нью Мун; 2014.

8. Меликян А.Л., Пустовая Е.И., Егорова Е.К., Калинина М.В., Колошейнова Т.И., Суборцева И.Н., Гилязитдинова Е.А., Двирнык В.Н. Дифференциальная диагностика тромбоцитопений Онкогематология. 2017; 12(1): 78 - 87.

9. Меликян А.Л., Пустовая Е.И., Цветаева Н.В., Птушкин В.В., Грицаев С.В. и др. Национальные клинические рекомендации по диагностике и лечению первичной иммунной тромбоцитопении (идиопатической тромбоцитопенической пурпуры) у взрослых (редакция 2016 г.). Гематология и трансфузиология. 2017; Приложение N 1: 1 - 24.

10. Tomohiro Kurokawa and Nobuhiro Ohkohchi Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017 May 14; 23(18): 3228 - 3239. PMID: 28566882 Published online 2017 May 14. doi: 10.3748/wjg.v23.i18.3228 PMCID: PMC5434428.

11. Protocole national de diagnostic et de soins (PNDS) Purpura thrombopenique immunologique de l'enfant et de l'adulte. Haute de - Mai 2009, 73p.

12. Carneiro-Sampaio M., Moraes-Vasconcelos D., Kokron C.M., Jacob C.M., Toledo-Barros M., Dorna M.B., et al. Primary immunodeficiency diseases in different age groups: a report on 1,008 cases from a single Brazilian reference center. J. Clin. Immunol. 2013; 33(4): 716 - 24.

13. Michel M., Cooper N., Jean C., Frissora C., Bussel B. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 2004, 103(3): 890 - 896. Doi: 10.11.1182/blood-2003-03-0900.

14. Liu Y, Chen S, Sun Y, Lin Q, Liao X, Zhang J, Luo J, Qian H, Duan L, Shi G. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. 2016 Dec; 95(50): e5565.

15. Matzdorff A., Eberl W., Kiefel V., T., Meyer O., Ostermann H., Pabinger-Fasching I., Rummel M.J., B. Immunthrombozytopenie (ITP). Onkopedia leitlinien - 2018, 46 p.

16. Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016 Jan 21; 127(3): 296 - 302; quiz 370. doi: 10.1182/blood-2015-07-659656.

17. Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Programm 2012; 2012: 191 - 7. Doi: 10.1182/ash education-2012.1.191.

18. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012 Aug 2; 120(5): 960 - 9. doi: 10.1182/blood-2011-12-309153.

19. Thota S., Kistangari G., Daw H., Spiro T. Immune thrombocytopenia in adults: an update. Cleve. Clin. J. Med. 2012; 79(9): 641 - 50. doi: 10.3949/ccjm.79a.11027.

20. Vianelli N, Palandri F, Polverelli N, Stasi R, Joelsson J, Johansson E, Ruggeri M, Zaja F et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013 Jun; 98(6): 875 - 80. 233.

21. Vianelli N., Galli M., de Vivo A., Intermesoli T., Giannini B., Mazzucconi M.G., et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90(1): 72 - 7.

22. Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia safety and efficasy. Br. J. Haematol. 2013; 161(3): 411 - 23. doi: 10.1111/bjh.12260.

23. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17; 121(3): 537 - 45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.

24. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013 Feb; 160(4): 538 - 46. doi: 10.1111/bjh.12169.

25. Cheng G., Saleh M.N., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393 - 402. doi: 10.1016/S0140-6736(10)60959-2.

26. Gonzales-Porras J.R., Mingot-Castellano M.E., Andrade M.M., Alonso R., Caparros I., et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. BrJHematology, 2015, 169, 111 - 116. Doi 10.1111/bjh.13266.

27. Khellaf M., Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F., Lefrere F, Fain O, Audia S., Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013; 98(6): 881 - 7. Doi: 10.3324/haematol.2012.074633.

28. Boruchov D.M., Gururangan S., Driscoll M.C., Bussel J.B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007; 110(10): 3526 - 31.

29. Hai Zhou et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015 Mar 5; 125(10): 1541 - 7. doi: 10.1182/blood-2014-06-581868.

30. Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T. et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Treatment for Adult Refractory Idiopathis Thrombocytopenic purpura. AmJHematology 2005, 78: 275 - 280.

31. Kuhne Thomas. Immune Thrombocytopenia (ITP)/Thomas Kuhne.-2nd edition - Bremen: UNI-MED, 2012 (INU-MED CSIENCE).

32. Arnold DM, Heddle NM, Carruthers J et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomised patients with immune thrombocytopenia. Blood. 2012; 119: 1356 - 1362.

33. Ghanima W, Khelif A, Waage A et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicenter, randomised, double blind, placebo-controlled trial. Lancet 2015; 385: 1653 - 1661 dx.doi.org/10.1016/S0140-6736(14)61495-1.

34. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chromic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74: 223 - 228.

35. Facon T, Caulier MT, Wattel E, Jouet JP, Bauters F, Fernaux P. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994; 86: 678 - 680.

36. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013 Jan 3; 121(1): 38 - 47. doi: 10.1182/blood-2012-08-448944.

37. Васильев С.А., Виноградов В.Л., Мазуров А.В., Маркова М.Л. Тромбоцитопении. Акушерство, гинекология и репродукция. 2014; N 2: с. 112 - 125.

38. Sukenik-Halevy R1, Ellis MH, Fejgin MD. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008 Mar; 63(3): 182 - 8. doi: 10.1097/OGX.0b013e318164013c.

39. George JN, Nester C, McIntosh J Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hem Education Program, 2015, Dec 5, 644 - 8.

40. Fakhouri F Pregnancy-related thrombotic microangiopathies: clues from complement biology, Transfusion and Apheres Sci, 2016, 54, p 199 - 202.

41. Кирсанова Т.В, Виноградова М.А, Федорова Т.А., Имитаторы тяжелой преэклампсии и HELLP синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология, 2016, 12, с 5 - 14.